Dong-A Socio Holdings Co., Ltd. (000640.KS)
KRW 110000.0
(4.86%)
KRW 110000.0
(4.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 141.36 Billion KRW | -29.74% |
| 2022 | 88.09 Billion KRW | -17.49% |
| 2021 | 120.93 Billion KRW | -43.56% |
| 2020 | 243.53 Billion KRW | 142.06% |
| 2019 | 101.96 Billion KRW | 176.12% |
| 2018 | -125.3 Billion KRW | -254.88% |
| 2017 | 76.5 Billion KRW | -61.92% |
| 2016 | 103.38 Billion KRW | 63.0% |
| 2015 | 90.67 Billion KRW | 110.28% |
| 2014 | 42.57 Billion KRW | -8.95% |
| 2013 | 55.44 Billion KRW | -60.1% |
| 2012 | 172.83 Billion KRW | 9.23% |
| 2011 | 154.76 Billion KRW | -4.49% |
| 2010 | 162.71 Billion KRW | 22.58% |
| 2009 | 132.36 Billion KRW | 46.72% |
| 2008 | 109.01 Billion KRW | -5.17% |
| 2007 | 97.78 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 53.87 Billion KRW | 96.93% |
| 2024 Q1 | 26.97 Billion KRW | 47.51% |
| 2023 Q2 | 96.94 Billion KRW | 21.32% |
| 2023 Q1 | 79.91 Billion KRW | 41159.74% |
| 2023 Q4 | 16 Billion KRW | -94.47% |
| 2023 FY | - KRW | -29.74% |
| 2023 Q3 | 289.22 Billion KRW | 198.34% |
| 2022 Q1 | 1.19 Billion KRW | -96.77% |
| 2022 Q2 | 17 Billion KRW | 1321.9% |
| 2022 Q3 | 25.6 Billion KRW | 50.53% |
| 2022 Q4 | 193.68 Million KRW | -99.24% |
| 2022 FY | - KRW | -17.49% |
| 2021 Q1 | 8.28 Billion KRW | -94.24% |
| 2021 Q2 | 21.23 Billion KRW | 156.25% |
| 2021 Q3 | 22.97 Billion KRW | 8.17% |
| 2021 Q4 | 37.08 Billion KRW | 61.45% |
| 2021 FY | - KRW | -43.56% |
| 2020 Q2 | 16.91 Billion KRW | 48.66% |
| 2020 FY | - KRW | 142.06% |
| 2020 Q1 | 11.38 Billion KRW | -21.21% |
| 2020 Q4 | 143.9 Billion KRW | 596.38% |
| 2020 Q3 | 20.66 Billion KRW | 22.14% |
| 2019 Q1 | 9.79 Billion KRW | 105.26% |
| 2019 FY | - KRW | 176.12% |
| 2019 Q4 | 14.44 Billion KRW | -36.06% |
| 2019 Q3 | 22.58 Billion KRW | 38.58% |
| 2019 Q2 | 16.3 Billion KRW | 66.45% |
| 2018 Q2 | 26.88 Billion KRW | 190.46% |
| 2018 Q1 | 9.25 Billion KRW | 867.21% |
| 2018 FY | - KRW | -254.88% |
| 2018 Q4 | -186.09 Billion KRW | -1227.95% |
| 2018 Q3 | 16.49 Billion KRW | -38.64% |
| 2017 FY | - KRW | -61.92% |
| 2017 Q4 | 957.1 Million KRW | -96.19% |
| 2017 Q3 | 25.09 Billion KRW | -6.66% |
| 2017 Q2 | 26.88 Billion KRW | 143.27% |
| 2017 Q1 | 11.05 Billion KRW | -36.51% |
| 2016 Q2 | 49.54 Billion KRW | 136.77% |
| 2016 FY | - KRW | 63.0% |
| 2016 Q4 | 17.4 Billion KRW | 1.51% |
| 2016 Q1 | 20.92 Billion KRW | 126.81% |
| 2016 Q3 | 17.14 Billion KRW | -65.39% |
| 2015 Q2 | 23.43 Billion KRW | 119.74% |
| 2015 FY | - KRW | 110.28% |
| 2015 Q1 | 10.66 Billion KRW | -50.02% |
| 2015 Q4 | 9.22 Billion KRW | -81.51% |
| 2015 Q3 | 49.88 Billion KRW | 112.87% |
| 2014 FY | - KRW | -8.95% |
| 2014 Q3 | 5.91 Billion KRW | -58.72% |
| 2014 Q2 | 14.32 Billion KRW | 17.13% |
| 2014 Q4 | 21.34 Billion KRW | 260.83% |
| 2014 Q1 | 12.23 Billion KRW | -28.48% |
| 2013 Q4 | 17.1 Billion KRW | -20.2% |
| 2013 FY | - KRW | -60.1% |
| 2013 Q1 | 14.26 Billion KRW | -86.84% |
| 2013 Q2 | 16.61 Billion KRW | 16.53% |
| 2013 Q3 | 21.43 Billion KRW | 28.96% |
| 2012 FY | - KRW | 9.23% |
| 2012 Q1 | 28.67 Billion KRW | 0.0% |
| 2012 Q2 | 14.54 Billion KRW | -49.26% |
| 2012 Q3 | 18.51 Billion KRW | 27.24% |
| 2012 Q4 | 108.37 Billion KRW | 485.51% |
| 2011 FY | - KRW | -4.49% |
| 2011 Q3 | 36.07 Billion KRW | 1.89% |
| 2011 Q1 | 38.45 Billion KRW | 0.0% |
| 2011 Q2 | 35.4 Billion KRW | -7.95% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 36.19 Billion KRW | -27.72% |
| 2010 FY | - KRW | 22.58% |
| 2010 Q2 | 50.08 Billion KRW | 58.01% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 31.69 Billion KRW | 0.0% |
| 2009 Q3 | 39.67 Billion KRW | 25.41% |
| 2009 Q2 | 31.63 Billion KRW | 30.67% |
| 2009 Q1 | 24.21 Billion KRW | 0.0% |
| 2009 FY | - KRW | 46.72% |
| 2009 Q4 | - KRW | -100.0% |
| 2008 FY | - KRW | -5.17% |
| 2008 Q3 | 28.7 Billion KRW | 33.06% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q1 | 14.14 Billion KRW | 0.0% |
| 2008 Q2 | 21.57 Billion KRW | 52.53% |
| 2007 Q1 | 10.98 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q2 | 22.74 Billion KRW | 107.04% |
| 2007 Q3 | 26.69 Billion KRW | 17.35% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2809.719% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 320.757% |
| HANDOK Inc. | 35.06 Billion KRW | -303.129% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 13737.6% |
| Yuhan Corporation | 127.43 Billion KRW | -10.932% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -276.759% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 751.821% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 56.279% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -2732.762% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -835.055% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -4032.271% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -3023.099% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -298.361% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2809.719% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 865.295% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -2056.594% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 386.79% |
| JW Holdings Corporation | 187.88 Billion KRW | 24.76% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 375.948% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 50.158% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -58.443% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 481.376% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -970.161% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -1095.178% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -657.787% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2809.719% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -157.151% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 14.28% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -58.443% |
| Yuhan Corporation | 127.43 Billion KRW | -10.932% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -322.286% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -1747.936% |
| Suheung Co., Ltd. | 77.02 Billion KRW | -83.522% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -58.443% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -285.877% |
| Korea United Pharm Inc. | 70.78 Billion KRW | -99.722% |
| CKD Bio Corp. | -1.63 Billion KRW | 8770.277% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -183.904% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -334.145% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -284.033% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 481.376% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -126.966% |
| Boryung Corporation | 114.28 Billion KRW | -23.691% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 562.453% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -835.055% |
| JW Lifescience Corporation | 50.82 Billion KRW | -178.116% |